The European Medicines Agency (EMA) has approved Ryzneuta (efbemalenograstim alfa) as a treatment to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for cancer. Ryzneuta is a granulocyte colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors and increases the production …
Read More
About The Author
